Apex Healthcare Bhd operates within the Drug stores and proprietary stores sector.
In addition to historical fundamental analyses, the complete report available to purchase compares Apex Healthcare Bhd with three other
drug stores in Asia:
China Jo-Jo Drugstores Inc
sales of 818.53 million Chinese Renmimbi [US$128.13 million]
of which 63%
was Retail Drugstores),
(16.69 billion Japanese Yen [US$152.18 million]
of which 56%
was Pharmaceutical segment), and
Sapporo Clinical Laboratory Inc.
based in JAPAN
(17.66 billion Japanese Yen [US$161.05 million]
of which 62%
was Dispensing Pharmacy Business).
During the first
quarter of 2021, sales at Apex Healthcare Bhd totalled
179.49 million Malaysian Ringgits.
This is a drop of 7.2%
from the 193.31 million Malaysian Ringgits in sales at the company during the first quarter in 2020.
This was the biggest quarterly decline in sales at Apex Healthcare Bhd in the previous 34 quarters.
During the year ended December of 2020, sales at
Apex Healthcare Bhd were 698.73 million Malaysian Ringgits (US$169.68 million).
a very small
increase of 1.4%
versus 2019, when the company's sales were 688.79 million Malaysian Ringgits.
This was the fifth consecutive year of sales increases at Apex Healthcare Bhd
(and since 2015, sales have increased a total of 33%).
Sales of Wholesale and Distribution saw an increase
that was more than double the company's growth rate: sales were up
4.1% in 2020, from
623.38 million Malaysian Ringgits to 648.95 million Malaysian Ringgits.
Not all segments of Apex Healthcare Bhd experienced an increase in sales in 2020:
sales of Corporate fell 72.5% to 2.23 million Malaysian Ringgits.
(However, this segment's sales were only a very small portion of the company's overall sales).
Apex Healthcare Bhd also experienced decreases in sales in
Manufacturing and Marketing (down 17.0% to 47.54 million Malaysian Ringgits)